AntimicrobialFDA Approved

Colistin (Polymyxin E)

Intravenous, Intramuscular, Inhalation

Overview

Colistin, also known as polymyxin E, is a cyclic polypeptide antibiotic structurally similar to polymyxin B, produced by Paenibacillus polymyxa. It disrupts the bacterial cell membrane by binding to lipopolysaccharide and displacing divalent cations, leading to increased permeability and cell lysis.

Mechanism of Action

The compound is administered as colistimethate sodium, an inactive prodrug that is hydrolyzed in vivo to the active colistin base. Its spectrum targets Gram-negative bacteria, particularly Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae..

Research Summary & Key Findings

Colistin was FDA approved in 1962 but fell out of favor due to nephrotoxicity; it has been reintroduced as a last-resort therapy for multidrug-resistant Gram-negative infections. Clinical trials and retrospective cohort studies have documented efficacy in ventilator-associated pneumonia and bloodstream infections caused by carbapenem-resistant organisms. Emergence of colistin resistance mediated by the plasmid-borne mcr-1 gene has been reported worldwide, raising concerns about its long-term utility.

Clinical Status

FDA Approved

Colistin (Polymyxin E) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

IntravenousIntramuscularInhalation

Related Peptides in Antimicrobial

Find a Provider

Find a verified provider who offers Colistin (Polymyxin E) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Colistin (Polymyxin E).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.